CIBMTR Announces Collaboration with Kite to Track Long-Term Outcomes Data for YESCARTA®
The CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced a new collaboration with Kite, a Gilead Company, focused on tracking long-term outcomes of patients treated with CAR T therapies. CIBMTR will collect and analyze long-term safety and efficacy data for YESCARTA in a commercial setting.
Be The Match BioTherapies Strengthens Partnership with Magenta Therapeutics
April 2018 – Be The Match BioTherapies® today announced that it has made its second equity investment in Magenta Therapeutics, a biotechnology company developing novel therapeutics to bring the curative power of bone marrow transplant to more patients. In addition, Be The Match BioTherapies announced that Amy Ronneberg, the organization’s president, has been appointed to Magenta’s Board of Directors.
Be The Match BioTherapies Expands Leadership Team with Promotions and New Hires
March 2018 – Be The Match BioTherapies® today announced the appointment of Chris McClain, MBA, to Vice President, New Business Development and Sales, and Steven Devine, M.D., a renowned stem cell transplant physician, as Medical Director. In addition, the company appointed Jamie Margolis, Ph.D., to Director, Product Development Operations.
Be The Match BioTherapies to present at CAR-T Congress USA on March 22
March 2018 – Be The Match BioTherapies® will be exhibiting and presenting at CAR-T Congress USA: A Collaborative Approach to Maximize the Potential of CAR-T, in Boston, Mass., March 21-22, 2018.
Be The Match BioTherapies to present at Cryogenic and Regenerative Medicine Commercialization Workshop
Feb. 2018 – Be The Match BioTherapies® will be presenting at the Cryogenic and Regenerative Medicine Commercialization Workshop in Tustin, Calif., Feb. 28 – March 1, 2018.
Be The Match BioTherapies Invests in Tmunity Therapeutics to Support Advancement of Next-Generation T Cell Immunotherapies
Jan. 2018 – Be The Match BioTherapies® today announced that it has invested in Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy.
Be The Match BioTherapies to present at Cell & Gene Therapy World Jan. 22-25
Jan. 2018 – Be The Match BioTherapies® will be exhibiting and presenting at the upcoming Phacilitate Cell & Gene Therapy World conference in Miami, Fla., Jan. 22-25, 2018.
Be The Match BioTherapies to exhibit at 59th ASH Annual Meeting & Exposition Dec. 9-11
Nov. 2017 – Be The Match BioTherapies will be exhibiting at the 2017 ASH Annual Meeting in Atlanta, Ga., Dec. 9-11, 2017.
Be The Match BioTherapies to present at Cell Therapy Manufacturing & Gene Therapy Congress on Dec. 6
Nov. 2017 – On Wednesday, Dec. 6, Amy Ronneberg, MBA, president of Be The Match BioTherapies, will present “Navigating the cell therapy supply chain – when exceptions are the norm,” at the Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam.
Be The Match BioTherapies Launches New Technology Platform for Cell Therapy Supply Chain Management
Oct. 2017 – Be The Match BioTherapies® today announced the launch of a new, implementation-ready technology platform for cell and gene therapies in clinical development or poised for commercialization.
Be The Match BioTherapies Presents at CAR-TCR Summit 2017 on Sept. 6
Sept. 2017 — Be The Match BioTherapies is participating in the CAR-TCR Summit 2017 in Boston, Mass., Sept. 5-8, 2017.
Be The Match BioTherapies Presents at Future Cell Therapy Commercialization Summit 2017
June 2017 — Be The Match BioTherapies® participated in the Future Cell Therapy Commercialization Summit 2017 in Boston, Mass., June 26-27.
Associate Bioinformatics Scientist participates in the first AI Genomics Hackathon
June 2017 — An Associate Bioinformatics Scientist for Be The Match BioTherapies® and the National Marrow Donor Program® (NMDP)/Be The Match® attended the first Artificial Intelligence (AI) Hackathon at Google’s Launchpad in San Francisco.
Be The Match BioTherapies Announces Collaboration Agreement with Magenta Therapeutics
May 2017 — Be The Match BioTherapies announced that it has entered into a strategic partnership with Magenta Therapeutics that aims to expand the use of stem cell transplant to disease indications including immune and blood-based diseases.
Be The Match BioTherapies Presents at Phacilitate Cell & Gene Therapy World 2017
Jan. 2017 — Be The Match BioTherapiesSM and our parent company, National Marrow Donor Program® (NMDP)/Be The Match®, participated in the Phacilitate Cell & Gene Therapy World 2017 in Miami, Fla.
National Marrow Donor Program (NMDP)/Be The Match Forms New Cellular Therapies Subsidiary
Jan. 2016 — NMDP/Be The Match announced the formation of Be The Match BioTherapies, a subsidiary that will focus on partnering with organizations pursuing new life-saving treatments in cellular therapy.
For media inquiries, contact email@example.com.
Are you attending one of the events below? Contact us – we’d like to connect with you at the event and learn how we can partner together.
May 2-5, 2018
Montreal, Quebec, Canada
May 16-19, 2018
June 1-5, 2018
June 4-7, 2018
August 27-31, 2018
September 4-7, 2018
January 21-25, 2019